StemCell Therapy

Newswise The protein Connexin 26 has been previously identified as being directly sensitive to Carbon dioxide and linked to conditions such as KIDS syndrome and deafness.

Thanks to a 686,956grant from the BBSRC, researchers from the School of Life Sciences at the University of Warwick will investigate the role of Connexin 26 (Cx26) in the control of breathing

They will highlight whether carriers of certain mutations of Cx26 are more likely to suffer from a reduced respiratory drive, and ability to regulate breathing

The relationship between the Cx26 gene and ability to regulate Carbon dioxide is to be explored by researchers from the School of Life Sciences, at the University of Warwick, thanks to a 686,956grant, from the BBSRC.

Professor Nicholas Dale, from the School of Life Sciences at the University of Warwick has previously identified that the protein Connexin 26 (Cx26) is directly sensitive to Carbon Dioxide (CO2).

Cx26 protein can have different mutations, which have previously been linked with KIDS syndrome, and deafness, this shows that both types of mutation can cause Cx26 to lose sensitivity to CO2.

Thanks to a 686,956grant from the BBSRC, researchers from the School of Life Sciences at the University of Warwick hope that their project, New tools for investigating connexin26 hemichannel function in physiological systems, may be able to directly identify a link between how Cx26 responds to CO2and its ability to control breathing. In the long term this could lead to understanding of how gene mutations interfere with this, and could help to develop new tests and treatments for breathing problems such as sleep apnoea.

Cx26 can respond to CO2in two different ways. This research aims to allow researchers to pin down which one of these two ways is involved in the control of breathing. To do this they will exploit how the Cx26 gene evolved from fish to man. Using the sequenced genome of Lungfish, researchers have previously researched Cx26 in the lungfish, which is closely related to the first existing species that crawled from water onto land and are air breathing. When studying the lungfish Cx26 protein researchers found that the lungfish Cx26 had only one way of responding to CO2, because the protein is slightly different, and has a long extension of 24 amino acids on one end of it.

Researchers plan to exploit this extension as a genetic tool, and hope that adding the extension of amino acids from lungfish Cx26 to human Cx26 will result in a subunit that can co-assemble with the native protein to remove one form of signalling. If this can be proven, researchers can look at breathing and see the extent to which one form of signalling contributes to breathing. If established it will lead to ways of treating the defects in the Cx26 molecule in humans carrying Cx26 mutations.

Professor Nicholas Dale, from the School of Life Sciences at the University of Warwick comments:

We hope that by the end of this four year project we can definitively establish how Cx26 controls breathing, and give new insight into how mutations of this key molecule could lead to altered control of breathing in humans.

If all goes well, in the long term it could provide new ways to diagnose breathing problems such as sleep apnoea, and introduce new clinical management strategies for Cx26 patients with mutations that affect CO2sensitivity to improve their quality of life.

View original post here:
Genetic mutation may hold answers to controlled breathing - Newswise

GREENVILLE, S.C.--(BUSINESS WIRE)--Premier Medical Laboratory Services (PMLS) announces today that they have been named one of the Top Genetic Diagnostic Companies of 2020 by Healthcare Tech Outlook, a leading national healthcare publication. The designation, earned by the Greenville, SC laboratory, comes with recognition for their providing the most advanced diagnostic testing solutions with accuracy and efficiency through employing the latest in science and technology.

One of the reasons PMLS was selected by the publication is that they are a highly complex laboratory with various types of test offerings to address many medical diagnostic needs. From COVID-19 PCR tests, antibody testing, pharmacogenomics, advanced cardiovascular testing, and their womens health & wellness and diabetes panels, all of PMLS tests are performed under one roof with cutting-edge laboratory equipment, providing a quick turnaround of results for physicians and patients.

We are honored to be designated as a top genetic diagnostic company of 2020 by Healthcare Tech Outlook, said Kevin Murdock, Founder of Premier Medical Laboratory Services. Our team of scientists and laboratory personnel is continually focused on providing the most advanced solutions to diagnostic testing demands, and to helping physicians provide top-level care to their patients.

Along with titling PMLS a top genetic diagnostic company, Healthcare Tech Outlook noted that Premier Medical Laboratory Services MDDiabeticPro panel includes the revolutionary DIABETESpredict test, which is a first of its kind predictive genetic test for type 2 diabetes developed in collaboration with world leading doctors and scientists of Harvard and MIT. The DIABETESpredict test is expected to mark a new era in diabetes prevention and care through evaluating the risk of the disease onset by examining individual genetic profiles and is currently available to the US through PMLS.

Along with their MDDiabeticPro panel, the article also recognizes PMLS full respiratory pathogen panel and GI panel, as well as their cardiovascular panel MDHeartPro, which more accurately depicts a patients overall heart health than a standard lipid panel that is often used by other laboratories. All of these testing services are conducted at PMLSs 40,000 sqft COLA and CLIA regulated laboratory in Greenville, South Carolina alongside their recently added portfolio of COVID-19 related tests.

By employing the latest in laboratory equipment, added staff and a highly advanced laboratory information management system, OnGen, PMLS has been able to expand their testing capacity and add quality PCR and antibody testing for COVID-19 to their diagnostic testing services. Additionally, the article explores how PMLS has found solutions to overcome COVID-19 supply chain shortages in coordination with their sister company, CPT Medical, who makes their own viral transport media and specimen collection kits.

Healthcare Tech Outlook states, PMLS is a highly sophisticated and top of the line advanced diagnostics lab with robust diagnostic services.

To read the full article, please visit this link: https://bit.ly/2POMkYW.

For more information about Premier Medical Laboratory Services, please visit http://www.PreMedInc.com or call 1.877.335.2455.

ABOUT PREMIER MEDICAL LABORATORY

Premier Medical Laboratory Services (PMLS) is a CLIA and COLA regulated laboratory based in Greenville, South Carolina focused on providing clinically meaningful results to medical practitioners. Premier Medical Laboratory Services offers a variety of highly specialized tests including: the only Type II Diabetes molecular predisposition test available in the U.S., advanced cardiovascular testing, hereditary cancer screening, carrier screening, womens health panels, pharmacogenomics, serum allergy testing, blood wellness, Hepatitis C genotyping, respiratory pathogens, gastrointestinal pathogens, and more. In addition to its specialty programs, Premier Medical Laboratory offers a comprehensive testing menu of general chemistry, immunoassay, and hematology tests. The company also is proud to offer a patient friendly billing policy.

For more information, please visit http://www.PreMedInc.com or call 1.877.335.2455.

View original post here:
Premier Medical Laboratory Services Named Among Top Genetic Diagnostic Companies of 2020 by Healthcare Tech Outlook - Business Wire

Inherited mutations in a gene that keeps nerve cells intact was shown, for the first time, to be a driver of a neuropathy known as Charcot-Marie-Tooth (CMT) disease. This finding is detailed in a study led by researchers in the Perelman School of Medicine, which published inNeurologyGenetics, an official journal of the American Academy of Neurology.

The findings, thanks to siblings treated at Penn since the late 1980s, present a clearer picture of the diseases genetic underpinnings that could inform the development of gene therapies to correct it.

The mutations in the gene known as dystonin (DST) add to a growing list of malfunctions found to cause their type of CMT, known as CMT2, which is defined by the loss of the nerve fibers, or axons, in the peripheral nerve cells. The researchers also showed that these mutations affect two key protein isoforms, BPAG1-a2 and BPAG1-b2, that are involved in nerve fiber function. Mutations in other isoforms of the same protein were previously tied to a blistering skin disease.

There are more than 100 mutations found to be associated with CMT, with likely many more out there.Past studies from Penn researchers haveidentified some of these mutations by studying patients treated at Penn Medicine.

We are determined to fill in the blanks of this giant jigsaw puzzle, says senior authorSteven S. Scherer, a professor of neurology. This latest paper is but one of many examples of where breakthroughs have happened between patients and the doctors at Penn and the support of different organizations and institutions to bring it all together."

Read more at Penn Medicine News.

Continued here:
New genetic cause of an inherited neuropathy discovered | Penn Today - Penn Today

This article was originally published here

Oncol Lett. 2020 Sep;20(3):2829-2839. doi: 10.3892/ol.2020.11843. Epub 2020 Jul 9.

ABSTRACT

The present study aimed to elucidate the genetic features of multiple lung cancer (MLC) and identify effective molecular markers for diagnosis using next generation sequencing (NGS). The present data may also inform patient treatment and prognosis. A total of 35 lesions were obtained from 17 patients with MLC. Based on lesion histology and NGS, 13 cases of multiple primary lung cancer (MPLC) were identified and 4 cases were classified as intrapulmonary metastasis (IPM). All 4 patients with IPM exhibited an epidermal growth factor receptor (EGFR) mutation and synchronous mutation of at least one tumor suppressor gene. The frequency and percentage of EGFR mutations, accompanied with tumor suppressor genes, were significantly higher in patients with IPM compared with MPLC. Furthermore, a high EGFR-heterogeneity score and male sex were risk factors of IPM occurrence. There were significant differences in mean EGFR mutation abundance alone, mutations of tumor suppressor genes and mutations of EGFR combined with tumor suppressor genes between patients with adenocarcinoma (ADC) and adenocarcinoma in situ (AIS). In conclusion, histological characteristics combined with genetic alterations may be an effective method for the diagnosis of MPLC and IPM, and NGS may serve as a useful diagnostic tool. MLC exhibited unique molecular characteristics, including higher rates of EGFR mutations, EGFR driver mutations accompanied with tumor suppressor gene mutations and the absence of anaplastic lymphoma kinase mutations, which may help distinguish between patients with MPLC or IPM. The present study hypothesized that the mean frequency of EGFR mutations, mutations of tumor suppressor genes and mutations of both EGFR and tumor suppressor genes may serve an important role in the development of AIS to ADC. The results of the present study highlight the potential underlying mechanisms of lung ADC development, which may assist with future elucidation of effective treatments to prevent the progression of lung cancer.

PMID:32782601 | PMC:PMC7400153 | DOI:10.3892/ol.2020.11843

More here:
Genetic features and application value of next generation sequencing in the diagnosis of synchronous multifocal lung adenocarcinoma - DocWire News

Bengaluru: MedGenome Lab has conducted a first-ever study on Indian population that validates a novel CAD-PRS (coronary artery disease-genome-wide polygenic risk score) to precisely predict the risk of developing a coronary artery disease/myocardial infarction (MI) using a persons genetic makeup.

MedGenome collaborated with researchers from Broad Institute of MIT and Harvard; Massachusetts General Hospital, Boston; Narayana Health, Bangalore; Eternal Hospital, Jaipur; Madras Medical Mission, Chennai; KMCH, Coimbatore and a few other institutes to conduct this first-ever research capturing the PRS of disease for South Asia populations and its findings are now published in the Journal of the American College of Cardiology (JACC).

Dr. Vedam Ramprasad, CEO, MedGenome Labs said Looking at all the available scientific evidence and our study results we are convinced that there exists a good opportunity to combine both clinical and genetic risks (polygenic risk score based) and significantly improve the primary prevention of coronary artery disease (CAD)."

The unique study is based on the principle of Genome-wide Polygenic Risk Score (PRS) which uses a genome-wide analysis of an individual to quantify the risk of developing heart disease.

It was conducted on the south Asian population in 1800 confirmed CAD cases and 1163 control samples from five centres across the country with a median age between 54 and 55 years.

The findings of this study have helped develop a CAD PRS that integrates information from millions of sites of common DNA variation into a single metric that can be calculated from birth and validate a scalable polygenic score framework in India.

This finding lays the scientific and operational foundation for clinical implementation not just for CAD but for other diseases. Such findings and methods developed can be used to screen large populations and high-risk individuals at a cost less than 5000 INR.

Knowingly, the polygenic risk is important to individuals with a family history of CAD, hypertension, diabetes, high cholesterol level, smoking habits, alcohol consumption, stressful lifestyle, as CAD results from a combination of these factors. A poor lifestyle and high polygenic risk could be a fatal combination and may result in early-onset CAD.

Go here to read the rest:
Experts develop a breakthrough genetic risk score for Heart Disease in South Asia - ETHealthworld.com

This article was originally published here

Breast Cancer Res Treat. 2020 Aug 9. doi: 10.1007/s10549-020-05859-0. Online ahead of print.

ABSTRACT

PURPOSE: To define the prevalence and risk factors of anxiety and examine rates and predictors of psychotherapy and integrative medicine service use in breast cancer survivors on aromatase inhibitors (AIs).

METHODS: Observational study of patients with histologically confirmed stage 0-III hormone receptor-positive breast cancer taking a third-generation AI at the time of enrollment. Patients completed self-report measures of anxiety and utilization of psychotherapy and integrative medicine services at a single time-point. We used multivariate logistic regression analyses to identify factors associated with anxiety and receipt of anxiety treatment services.

RESULTS: Among the 1085 participants, the majority were younger than 65 years of age (n = 673, 62.0%) and white (n = 899, 82.9%). Approximately one-third (30.8%) reported elevated anxiety ( 8 on the anxiety subscale of the Hospital Anxiety and Depression Scale). Of patients with elevated anxiety, only 24.6% reported receiving psychological counseling, 25.3% used integrative medicine services, and 39.8% received either type of treatment since their diagnosis. Patients with an education level of high school or less were less likely to receive psychological counseling (AOR, 0.43, 95% CI 0.19-0.95) and integrative medicine services (OR 0.30, 95% CI 0.12-0.72) than patients with higher levels of education.

CONCLUSIONS: Anxiety is common in breast cancer patients treated with AIs yet the majority of anxious patients do not receive evidence-based treatment, even when these treatments are available. Better systematic anxiety screening and treatment initiation are needed to reduce disparities in care by education level.

PMID:32772224 | DOI:10.1007/s10549-020-05859-0

Link:
Receipt of psychological counseling and integrative medicine services among breast cancer survivors with anxiety - DocWire News

One of the many untold effects of the COVID-19 pandemic is the toll it is taking on patients without COVID. During the initial wave of COVID cases, staying home was universally urged to protect people from exposure to the infection, but, in the process, many people ignored serious medical issues that should have sent them to their provider or an emergency room. One survey found that almost one-third of people admitted to delaying or avoiding emergency care even though they needed it. While access and affordability continue to be a huge problem in healthcare, many today are wondering if it is safe to see the doctor for routine visits yet.

Join Kris Kington Barker as she hosts the program from homeamid concerns about the spread of theCOVID-19 virus. She will be speaking with Susan Polk, owner of Susan Polk InsuranceAgency and Lindsey Faucette,DO, FAAFP, Chief Medical Officer at SLO Health-Family and Integrative Medicine as they discuss how COVID-19 is impacting healthcare access, utilization and insurance coverage for non COVID care.

You are invited to listen, learn and participate in the conversationtoday, Thursday, between 1-2 pm. Call in and be part of the discussion at(805) 549-8855 or email questions to voices@kcbx.org.

Broadcast date: 8/13/20

Central Coast Voices is sponsored by ACTION for Healthy Communities in collaboration with KCBX and made possible through underwriting by Joan Gellert-Sargen.

Read more:
Central Coast Voices: COVID-19 and its impact on non COVID care - KCBX

Your doctor diagnoses you with high blood pressure, orders various tests and sends you home with a prescription to keep it under control.

Thats the old-school model of a typical healthcare experience.

UCI Health, with its emphasis on evidence-based integrative health, is new-school, with world-class specialists who treat the immediate symptoms of heart disease and other conditions, as well as the mind and spirit of patients.

In addition to running traditional tests, integrative health doctors and nurses also conduct sophisticated diagnostic assessments and examine patients health history and lifestyle in depth including diet, exercise habits and other factors to devise a treatment plan.

Its a whole-person approach, says Dr. Ailin Barseghian, who specializes in preventive cardiology and integrative heart health at UCIs Susan Samueli Integrative Health Institute.

An assistant clinical professor in the School of Medicine, she is one of many physicians who will be offering this integrative approach to wellness at UCI Health Newport Beach, a multispecialty medical office opening in August in the Newport Center business complex surrounding Fashion Island.

The emphasis on integrative health at the new clinic, located at 2161 San Joaquin Hills Road, is being spearheaded by UCI Health cardiologist Shaista Malik, executive director of the Susan Samueli Integrative Health Institute and founding associate vice chancellor for integrative health at UCIs Susan and Henry Samueli College of Health Sciences.

UCI Health Newport Beachs services will include integrative cardiology, gastroenterology, dermatology and pain management, along with such therapies as acupuncture, massage, naturopathic medicine, mindfulness and yoga.

Reducing risk factors

With advanced testing and other supportive treatments, Barseghian says, we can personalize care for each individual and help reduce their risk factors for cardiovascular disease.

To be sure, traditional cardiologists also recommend that patients improve their diets, exercise a certain number of times each week and make other lifestyle changes, she says, but with integrative cardiology, we work as a team that includes an exercise specialist, a dietitian and other therapists to help guide people.

With a patient who has high blood pressure, for example, the goal is to get to the root of the problem, Barseghian explains: We assess nutrition and fitness, as well as sleep patterns and any possible stressors such as whether someone is going through a divorce or a difficult time on the job to see if theres an underlying cause. We might also try acupuncture, which studies show can lower blood pressure if a regular regimen is maintained.

Whats different about UCI Health Newport Beach, she adds, is that specialty care and most integrative health services are available in one location. The clinic is 7,000 square feet and will employ 13 non-provider staff members, with about five providers working each day.

Its certainly a unique resource in this area, Barseghian says. Some of these complementary therapies, like acupuncture, arent new. Were just including them when it comes to assessing the overall health of our patients.

Dedicated physicians

Barseghian, who graduated from New York Medical College, did most of her training at UCI. She completed an internal medicine residency and cardiovascular disease fellowship at UCI Medical Center, followed by a fellowship in interventional cardiology at Lenox Hill Heart and Vascular Institute in New York City.

Shes been on the faculty at UCI for five years and currently is seeing patients at the Susan Samueli Integrative Health Institute in Costa Mesa, UCI Health Tustin and the UCI Health Cardiovascular Center in Orange.

When I did my general cardiology training here, she says, I linked up with Dr. Malik. She had already started the preventive cardiology program, and I focused my training on that. She was my mentor.

Stress management, Barseghian notes, is an important element of integrative cardiology.

For instance, she says, its not uncommon to see blood pressure or a heart rate change based on stressors, especially prolonged or situational stress. And those are hard to manage with traditional pharmaceutical therapy, because the stressor still can surpass the medication benefit. So the focus then becomes finding ways to manage that stress to avoid a surge in blood pressure.

I love my work, Barseghian continues. In medicine, the biggest drive is your connection with your patients and having the opportunity to help and guide them. As an interventional cardiologist, I put in stents and treat heart attacks, and I see the disease progression. Being able to concentrate on prevention from the integrative standpoint just gives me more tools beyond the traditional pharmacological one.

The rest is here:
Treating mind, body and spirit - UCI News

RENO, Nev. Nevada ENT and Hearing Associates announced Aug. 3 that Dr. Keely Chevallier joined the Reno-based practice.

According to an Aug. 3 press release, Dr. Chevallier, a Nevada native, comes from David Grant Medical Center at Travis Air Force Base, where she served as an Active Duty Air Force officer for four years, most recently as the Officer in Charge of the combined ENT, Audiology and Speech Language Pathology Clinic, and the Surgical Champion for the Hospitals Informatics Steering Committee.

She served a tour in Afghanistan in 2018 as the only NATO forces ENT in the country. During this time, she took care of patients including U.S. Service Members, NATO forces and Afghan troops, providing care for traumatic injuries, respiratory failure and all diseases of the ears, nose, and throat.

Dr. Chevallier received a Bachelor of Arts in integrative biology from University of California, Berkeley. She received her Doctor of Medicine degree from University of Colorado, School of Medicine in Aurora, Colorado and completed her residency in Otolaryngology/Head and Neck Surgery at University of Utah Hospital in Salt Lake City, Utah.

Dr. Chevallier has been a member of the Alpha Omega Alpha Medical Honor Society since 2009 and has been board certified with the American Board of Otolaryngology since 2017.

Here is the original post:
People: Keely Chevallier joins Nevada ENT and Hearing Associates - Northern Nevada Business Weekly

Cannabis with THC levels over 10 per cent became the strongest predictor of success in treating migraine- and headache-related pain.

For the first time, researchers have focused on dried cannabis flower as treatment for headaches and migraines.

Published in the Journal of Integrative Medicine, the study examined, in real time, the associations between different product characteristics and changes in symptom intensity following cannabisuse.

Interestingly, results showcased that flower was, indeed, effective for migraines, but the specifics of the cannabis plant (gender, age and combustion methods) may decrease effectiveness.

One key finding determined that cannabis with tetrahydrocannabinol (THC) levels over 10 per cent became the strongest predictor of success in treating migraine- and headache-related pain with cannabis.

Additionally, the C. indica strain offered greater success with individuals in the study over its C. sativa counterpart. Overall, for those seeking migraine relief and for healthcare professionals looking to treat those who have headaches, the study could be an important conversation starter for better outcomes against pain.

Results of the study offer insight into how cannabis looks to not only alleviate, but could eliminate, migraine pain for some users. With more than 94 per cent of users experiencing symptom relief within two hours, the study has brought to light deeper conversations around cannabis role in pain and quality-of-life for those experiencing headache-related disorders.

The research joins another study that looked into the prolonged use of cannabis for individuals who suffer migraines. Published in May in Brain Sciences, the study found that frequent cannabis use decreased migraine frequency.

Another study found that frequent cannabis use decreased migraine frequency. / Photo: iStock / Getty Images PlusiStock / Getty Images Plus

These findings indicate that MC [medical cannabis] results in long-term reduction of migraine frequency in more than 60 per cent of treated patients and is associated with less disability and lower anti-migraine medication intake.

Cannabis and CBD have attracted interest in migraine treatments in the last few years with organizations looking to alternative medicine to offer a needed solution for those who dont want to use opioids.

The Migraine Research Foundation gave Dr. Nathaniel Schuster from the University of California San Diego funding for his research on cannabis in 2018. Additionally, the American Headache Society and the American Migraine Foundation have both expressed the need for more research around cannabis and CBD for migraine relief.

The FreshToast.com, a U.S. lifestyle site that contributes lifestyle content and, with their partnership with 600,000 physicians via Skipta, medical marijuana information to The GrowthOp.

Want to keep up to date on whats happening in the world of cannabis?Subscribeto the Cannabis Post newsletter for weekly insights into the industry, what insiders will be talking about and content from across the Postmedia Network

Go here to see the original:
What a new study reveals about cannabis and migraines - The GrowthOp

Yoga improves symptoms of generalized anxiety disorder, a condition with chronic nervousness and worry, suggesting the popular practice may be helpful in treating anxiety in some people.

Led by researchers at NYU Grossman School of Medicine, a new study found that yoga was significantly more effective for generalized anxiety disorder than standard education on stress management, but not as effective as cognitive behavioral therapy (CBT), the gold standard form of structured talk therapy that helps patients identify negative thinking for better responses to challenges.

Generalized anxiety disorder is a very common condition, yet many are not willing or able to access evidence-based treatments, says lead study author Naomi M. Simon, MD, a professor in the Department of Psychiatry at NYU Langone Health. Our findings demonstrate that yoga, which is safe and widely available, can improve symptoms for some people with this disorder and could be a valuable tool in an overall treatment plan.

For the study, 226 men and women with generalized anxiety disorder were randomly assigned to 3 groupsCBT, Kundalini yoga, or stress management education, a standardized control technique.

After three months, both CBT and yoga were found to be significantly more effective for anxiety than stress management. Specifically, 54 percent of those who practiced yoga met response criteria for meaningfully improved symptoms compared with 33 percent in the stress education group. Of those treated with CBT, 71 percent met these symptom improvement criteria.

However, after six months of follow-up, the CBT response remained significantly better than stress education (the control therapy), while yoga was no longer significantly better, suggesting CBT may have more robust, longer-lasting anxiety-reducing effects. The results were published online August 12 in JAMA Psychiatry.

The study involved an evidence-based protocol for CBT treatment of generalized anxiety disorder, including psychoeducation, cognitive interventions (focused on identifying and adapting maladaptive thoughts and worrying), and muscle relaxation techniques.

Kundalini yoga included physical postures, breathing techniques, relaxation exercises, yoga theory, and meditation and mindfulness practice.

The stress management education control group received lectures about the physiological, psychological, and medical effects of stress, as well as the antianxiety effects of lifestyle behaviors, such as reducing alcohol and smoking, and the importance of exercise and a healthy diet. Homework consisted of listening to educational material about stress, nutrition, and lifestyle.

Each treatment was administered in groups of 3 to 6 participants, over weekly 2-hour sessions for 12 weeks with 20 minutes of daily homework assigned.

According to researchers, generalized anxiety disorder is a common, impairing, and undertreated condition, currently affecting an estimated 6.8 million Americans. While most people feel anxious from time to time, it is considered a disorder when worrying becomes excessive and interferes with day-to-day life. CBT is considered the gold standard first-line treatment. Medications, including antidepressants and sometimes benzodiazepines, may also be used. Yet, not everyone is willing to take medication, which can have adverse side effects, and there are challenges with accessing CBT for many, including lack of access to trained therapists and long waitlists.

Many people already seek complementary and alternative interventions, including yoga, to treat anxiety, says Dr. Simon. This study suggests that at least short-term there is significant value for people with generalized anxiety disorder to give yoga a try to see if it works for them. Yoga is well-tolerated, easily accessible, and has a number of health benefits.

According to Dr. Simon, future research should aim to understand who is most likely to benefit from yoga for generalized anxiety disorder to help providers better personalize treatment recommendations.

We need more options to treat anxiety because different people will respond to different interventions, and having more options can help overcome barriers to care, she says. Having a range of effective treatments can increase the likelihood people with anxiety will be willing to engage in evidence-based care.

Along with Dr. Simon, other authors of this study are Stefan G. Hofmann of Boston University; David Rosenfield at Southern Methodist University in Dallas; Susanne S. Hoeppner and Eric Bui of Massachusetts General Hospital, Harvard Medical School in Boston; Elizabeth A. Hoge of Georgetown University Medical Center in Washington, D.C.; and Sat Bir S. Khalsa of Brigham and Womens Hospital, Harvard Medical School in Boston.

Funding for the work came from the National Center for Complementary and Integrative Health grants R01 AT007258 and R01 AT007257 to Dr. Simon and Dr. Hofmann.

Ashley WelchPhone: 212-404-3511ashley.welch@nyulangone.org

View post:
Yoga Shown to Improve Anxiety, Study Finds | NYU Langone News - NYU Langone Health

According to latest research report on Global Health Coaching Market report provides information related to market size, production, CAGR, gross margin, growth rate, emerging trends, price, and other important factors. Focusing on the key momentum and restraining factors in this market, the report also provides a complete study of future trends and developments in the market.

The Health Coaching report contains all the details of the expected market dynamics and new market opportunities due to the COVID-19 outbreak. Stratagem Market Insights tried to cover all the market analysis of annual economic growth in the latest report on the Health Coaching market.

According to analysts, the growth of the Health Coaching market will have a positive impact on the global platform and will witness gradual growth over the next few years. This report study incorporates all the market growth and restraining factors along with the important trends mentioned between 2020 and 2025.

Request Sample Copy of this Report @ https://www.express-journal.com/request-sample/168077

Market segmentation:

The Health Coaching market has been segmented into a variety of essential industries including applications, types, and regions. In the report, each market segment is studied extensively, taking into account market acceptance, value, demand, and growth prospects. Segmentation analysis allows customers to customize their marketing approach to make better orders for each segment and identify the most potential customers.

Global Health Coaching Market Segmentation by Application:

Global Health Coaching Market Segmentation by Product:

Competitive Landscape

This section of the report identifies various major manufacturers in the market. It helps readers understand the strategies and collaborations players are focusing on fighting competition in the marketplace. The comprehensive report gives a microscopic view of the market. The reader can identify the manufacturers footprint by knowing about the manufacturers global revenue, the manufacturers global price, and the manufacturers production during the forecast period.

The major manufacturers covered in this report:

Regional Insights of Health Coaching Market:

In terms of geography, this research report covers almost all major regions around the world such as North America, Europe, South America, Middle East, Africa, and the Asia Pacific. Europe and North America are expected to increase over the next few years. Health Coaching markets in the Asia-Pacific region are expected to experience significant growth during the forecast period. Advanced technology and innovation are the most important characteristics of North America and the main reason why the United States dominates the world market. The Health Coaching market in South America is also expected to expand in the near future.

Years considered for this report:

Important Facts about Health Coaching Market Report:

Questions Answered by the Report:

Request Customization on This Report @ https://www.express-journal.com/request-for-customization/168077

More here:
Global Health Coaching Market Potential Growth, Share, Demand and Analysis of Key Players- Research Forecasts to 2025 - Express Journal

By Deepali Singh

Are acidity and constipation causing you discomfort? Experts list a few self-help techniques to get respite

All that late-night bingewatching and midnight snacking has not only caused our sleeping patterns to go haywire, but its also one of the reasons for more and more people complaining about stomach-related ailments.

A sedentary lifestyle coupled with irregular eating hours and poor dietary patterns are reasons enough for the rise in several tummy issues such as bloating, acidity and constipation, says Dr Roy Patankar, gastroenterologist and director of Zen Multi Speciality Hospital, Chembur.

With limited physical activity, lesser access to fresh vegetables and fruits, increase in consumption of junk food, late-night snacking and anxiety related to Covid-19, peoples lifestyle has undergone a major change in these times, says Dr Patankar. If there are serious symptoms such as black coloured stool, weight loss, vomiting or unexplained pain that lasts for too long or the problem persists for more than 48 hours, then we suggest tele-consultations with the doctor. However, before you rush to the doctor, a few self-help techniques might come in handy to keep your digestive system in top order.

Eat right

Apart from keeping a whole lot of health problems at bay, a nutritious diet consisting of vegetables, fruits, nuts, seeds and whole grains are recommended to keep your stomach in order too. To combat acidity issues, Luke Coutinho, holistic lifestyle coach, Integrative Medicine suggests alkaline foods such as cucumber, fennel seeds, coriander seed tea and kokum infused water. He also suggests lukewarm water for constipation problems and adequate fibre, as that helps form the bulk of the stool. Certain spices such as asafoetida, cumin, and bishops weed are known to have carminative properties; they reduce the gas-forming ability of food, he adds. Abstaining from excess tea and coffee is a good idea as it makes our system acidic, he adds. While including raw food is good, overdoing it in the name of fibre isnt advised, as it can irritate the walls of our digestive system. Sugar and junk foods also alter the ratio of good and bad bacteria in the gut and feed the bad bacteria. They can also cause inflammation of the gut linings, he adds.

With the rainy weather being a good excuse to binge on fried snacks, a common scenario is to reheat the oil for cooking. But reheating the oil again and again can generate a lot of free radicals thereby leading to inflammation or exacerbating already existing inflammation, and therefore, should be avoided, says Coutinho.

At times, overdoing the good stuff may also lead to trouble. According to Dr Patankar, consuming large quantities of raw garlic and ginger which some people have been doing to strengthen their immune system can also play havoc with the digestive system.

Some basic rules

Drinking adequate amounts of water and focusing completely on meals without multi-tasking are also good habits to inculcate for a healthy digestive system. Coutinho also suggests smart fasting to reset your digestive system. It gives our digestion space and opportunity to heal, cleanse, and recover, he adds. By far, a lifestyle change of 12-hour gap between dinner and next days meal is one of the most effective lifestyle changes ever made for acidity, constipation, bloating and indigestion.

Read more:
THAT FIRE IN YOUR BELLY - Mumbai Mirror

In addition to low-glycemic fruits and veggies, as part of your balanced diet, it's important to include plenty of fiber and a variety of macronutrients.

"Getting enough fiber each day is essential for healthy blood sugar levels," says Frances Largeman-Roth, RDN, nutrition expert and author of Smoothies & Juices: Prevention Healing Kitchen. "Adults should get 25 to 35 grams each day, but most of us fall short. If you spread it out to five meals (including snacks) a day, that's 5 grams of fiber per meal."

However, if you're struggling to maintain a consistent nutrient intake (fiber or otherwise), one great solution is a greens powder, which includes dried, powdered forms of various vegetables, fruits, and other nutritious ingredients.* One study found that adding a vegetable powder to a high-carbohydrate diet helped buffer the short-term glucose and insulin response.*

mindbodygreen's organic veggies+, in particular, was designed to help support healthy blood sugar. In addition to a number of nutritious leafy greens and veggies, it features a fiber blend of flaxseed and inulin.

"It also provides cinnamon bark, which promotes healthy blood sugar balance by slowing the breakdown of carbohydrates during digestion,*" Jessica Cording, M.S., R.D., CDN, previously told mindbodygreen. In fact, some studies suggest that cinnamon promotes healthy blood sugar by increasing insulin sensitivity, or making insulin more efficient at moving glucose into cells.*

Read the original:
3 Expert-Backed Ways To Support Healthy Blood Sugar Levels - mindbodygreen.com

More than 500 clinical trials are under way world-wide in the race to find an effective treatment for Covid-19. Everybody wants it; nobody has ityet. But one of the most promising therapies for Covid-19 patients uses medicinal signaling cells, or MSCs, which are found on blood vessels throughout the body.

In preliminary studies, these cells cut the death rate significantly, particularly in the sickest patients. With a powerful 1-2-3 punch, these cells eliminate the virus, calm the immune overreaction known as a cytokine storm, and repair damaged lung tissuea combination offered by no other drug. This type of regenerative medicine could be as revolutionary as Jonas Salks polio vaccine.

In one pilot study in March, doctors at Mount Sinai Hospital in New York treated a dozen severely ill Covid-19 patients on ventilators with MSCs. Two infusions modulated their hyperactive immune systems, and 83% of those patients survived. With such promising results, the team at Mount Sinai and the supplier of the cells, Mesoblast Ltd., won Food and Drug Administration clearance and National Institutes of Health funding to conduct a randomized trial on 300 patients. The first patients in the trial received the treatment in early May.

A July 10 article in the Lancet reported on 13 critically ill Covid-19 patients also treated with MSCs. Eleven of the 13 patients livedan 85% survival rate, which mirrors the results from Mount Sinai. The number of virus-fighting T-cells rose even as inflammation fell, suggesting that these cells can control the immune response as needed. In addition, chest X-rays showed that the drug repaired lung tissue, in some cases within 48 hours.

Healing tissue is essential because the cytokine battle with the Covid-19 virus is so vicious that it punches holes in the delicate lung membranes, allowing the virus to flood into the bloodstream and body cavities. These holes must be repaired, as virus leaks create some of the complications not usually associated with respiratory infectionsblood clotting, heart attacks, stroke and multiple organ failure, which cause about 40% of Covid-19-related deaths. Blood-vessel density, and thereby the number of MSCs, decreases as we age, gain weight or develop diseases, which may explain why the elderly and those with chronic health conditions are faring worst.

Read the original post:
The Treatment That Could Crush Covid - The Wall Street Journal

The global stem cell and regenerative medicines market should grow from $21.8 billion in 2019 to reach $55.0 billion by 2024 at a compound annual growth rate (CAGR) of 20.4% for the period of 2019-2024.

Report Scope:

The scope of this report is broad and covers various type of product available in the stem cell and regenerative medicines market and potential application sectors across various industries. The current report offers a detailed analysis of the stem cell and regenerative medicines market.

The report highlights the current and future market potential of stem cell and regenerative medicines and provides a detailed analysis of the competitive environment, recent development, merger and acquisition, drivers, restraints, and technology background in the market. The report also covers market projections through 2024.

Request For Report sample @ https://www.trendsmarketresearch.com/report/sample/11723

The report details market shares of stem cell and regenerative medicines based on products, application, and geography. Based on product the market is segmented into therapeutic products, cell banking, tools and reagents. The therapeutics products segments include cell therapy, tissue engineering and gene therapy. By application, the market is segmented into oncology, cardiovascular disorders, dermatology, orthopedic applications, central nervous system disorders, diabetes, others

The market is segmented by geography into the following regions: North America, Europe, Asia-Pacific, South America, and the Middle East and Africa. The report presents detailed analyses of major countries such as the U.S., Canada, Mexico, Germany, the U.K. France, Japan, China and India. For market estimates, data is provided for 2018 as the base year, with forecasts for 2019 through 2024. Estimated values are based on product manufacturers total revenues. Projected and forecasted revenue values are in constant U.S. dollars, unadjusted for inflation.

Request For Report Discounts @ https://www.trendsmarketresearch.com/report/discount/11723

Report Includes:

28 data tables An overview of global markets for stem cell and regenerative medicines Analyses of global market trends, with data from 2018, estimates for 2019, and projections of compound annual growth rates (CAGRs) through 2024 Details of historic background and description of embryonic and adult stem cells Information on stem cell banking and stem cell research A look at the growing research & development activities in regenerative medicine Coverage of ethical issues in stem cell research & regulatory constraints on biopharmaceuticals Comprehensive company profiles of key players in the market, including Aldagen Inc., Caladrius Biosciences Inc., Daiichi Sankyo Co. Ltd., Gamida Cell Ltd. and Novartis AG

Summary

The global market for stem cell and regenerative medicines was valued at REDACTED billion in 2018. The market is expected to grow at a compound annual growth rate (CAGR) of REDACTED to reach approximately REDACTED billion by 2024. Growth of the global market is attributed to the factors such as growingprevalence of cancer, technological advancement in product, growing adoption of novel therapeuticssuch as cell therapy, gene therapy in treatment of chronic diseases and increasing investment fromprivate players in cell-based therapies.

In the global market, North America held the highest market share in 2018. The Asia-Pacific region is anticipated to grow at the highest CAGR during the forecast period. The growing government funding for regenerative medicines in research institutes along with the growing number of clinical trials based on cell-based therapy and investment in R&D activities is expected to supplement the growth of the stem cell and regenerative market in Asia-Pacific region during the forecast period.

Reasons for Doing This Study

Global stem cell and regenerative medicines market comprises of various products for novel therapeutics that are adopted across various applications. New advancement and product launches have influenced the stem cell and regenerative medicines market and it is expected to grow in the near future. The biopharmaceutical companies are investing significantly in cell-based therapeutics. The government organizations are funding research and development activities related to stem cell research. These factors are impacting the stem cell and regenerative medicines market positively and augmenting the demand of stem cell and regenerative therapy among different application segments. The market is impacted through adoption of stem cell therapy. The key players in the market are investing in development of innovative products. The stem cell therapy market is likely to grow during the forecast period owing to growing investment from private companies, increasing in regulatory approval of stem cell-based therapeutics for treatment of chronic diseases and growth in commercial applications of regenerative medicine.

Products based on stem cells do not yet form an established market, but unlike some other potential applications of bioscience, stem cell technology has already produced many significant products in important therapeutic areas. The potential scope of the stem cell market is now becoming clear, and it is appropriate to review the technology, see its current practical applications, evaluate the participating companies and look to its future.

The report provides the reader with a background on stem cell and regenerative therapy, analyzes the current factors influencing the market, provides decision-makers the tools that inform decisions about expansion and penetration in this market.

More Info of Impact Covid19 @ https://www.trendsmarketresearch.com/report/covid-19-analysis/11723

Go here to read the rest:
Stem Cell And Regenerative Therapy Market Industry Outlook, Growth Prospects and Key Opportunities - Kentucky Journal 24

MIRAMAR, Fla., Aug. 13, 2020 (GLOBE NEWSWIRE) -- Generex Biotechnology Corporation (www.generex.com) (OTCQB:GNBT) is pleased to announce that physicians at Yale University School of Medicine and the VA Connecticut Healthcare System have published a paper in the Journal of Vascular Surgery Cases and Innovative Techniques describing the use of Excellagen wound conforming collagen matrix as part of a hybrid surgical protocol to repair a femoral artery pseudoaneurysm. Femoral artery pseudoaneurysms are the most common complication following cardiac and peripheral angiographic procedures, with an incidence ranging from 2-6% following interventional procedures. Apseudoaneurysm occurs when a blood vessel wall is injured and the leaking blood collects in the surrounding tissue. While small pseudoaneurysms (< 2 cm) often thrombose (clot) spontaneously, larger pseudoaneurysms involving blood sac expansion, vascular symptoms, and surrounding hematoma confer a risk of rupture and warrant surgical intervention to prevent serious complications including death.

Naiem Nassiri, MD of Yale University School of Medicine commented, Excellagens purity, versatility, and user-friendly application render it ideal for a diverse array of indications for collagen delivery in vascular surgery. For us to date, these have included, but are not limited to re-explored wounds; topical hemostatic agent by virtue of dead space elimination and granulation tissue formation; a regular adjunct to negative pressure dressings; a precursor to skin grafting; and topical applications in cosmetically sensitive areas following embolotherapeutic procedures.

Rapid healing of the vascular surgical repair site is needed to prevent recurrence or progression of the pseudoaneurysm. Using Excellagen from Generexs subsidiary, Olaregen Therapeutix, the surgeons at Yale and the Connecticut VA demonstrated a simple, safe and effective approach to pseudoaneurysm repair. The novel hybrid technique avoided surgical exploration in the face of active hemorrhage, expedited culprit vessel identification, avoided the need for remote percutaneous arterial puncture, reduced blood loss, and minimized overall operative time.

Excellagen is a ready to use 3-dimensional wound conforming matrix that supports a favorable wound healing environment. It is designed to activate collagen, accelerate granulation, and promote new tissue growth by providing a structural scaffold for cellular migration and proliferation. Excellagen has been shown to trigger the localized release of endogenous growth factors including Platelet-Derived Growth Factor (PDGF), a key biological mediator of wound healing.

Anthony Dolisi, CEO of Olaregen commented, We have been working closely with the VA system using case studies to evaluate the use of Excellagen in numerous wound management applications, including diabetic foot ulcers and vascular surgery procedures. As this peer-reviewed publication demonstrates, Excellagen can be used successfully in complex vascular surgeries like pseudoaneurysm repair to promote healing that lead to better patient outcomes. We look forward to engaging with the VA and the vascular surgery community to introduce our FDA-cleared cellular tissue product Excellagen into their surgical protocols for the benefit of patients with life-threatening conditions.

About Generex Biotechnology Corp. Generex Biotechnology is an integrated healthcare holding company with end-to-end solutions for patient centric care from rapid diagnosis through delivery of personalized therapies. Generex is building a new kind of healthcare company that extends beyond traditional models providing support to physicians in an MSO network, and ongoing relationships with patients to improve the patient experience and access to optimal care.

In addition to advancing a legacy portfolio of immune-oncology assets, medical devices, and diagnostics, the Company is focused on an acquisition strategy of strategic businesses that complement existing assets and provide immediate sources of revenue and working capital.

About Olaregen Therapeutics

Olaregen Therapeutix, Inc. is a regenerative medicine company focused on the development, manufacturing and commercialization of products that fill unmet needs in the current wound care market. The company aims to provide advanced healing solutions that substantially improve medical outcomes while lowering the overall cost of care. Olaregen's first product introduction, Excellagen (flowable dermal matrix) is a topically applied product for dermal wounds and other indications. Excellagen is a FDA 510K cleared device for a broad array of dermal wounds, including partial and full thickness wounds, pressure ulcers, venous ulcers, diabetic ulcers, chronic vascular ulcers, tunneled/undermined wounds, surgical wounds (donor sites/ grafts, post-Mohs surgery, post-laser surgery, podiatric, wound dehiscence), trauma wounds (abrasions, lacerations, second-degree burns and skin tears) and draining wounds, enabling Olaregen to market Excellagen in multiple vertical markets. in bone and joint regeneration comprise the current pipeline. The company's mission is to become a significant force in regenerative medicine and advance the science of healing.

Cautionary Note Regarding Forward-Looking Statements

This release and oral statements made from time to time by Generex representatives in respect of the same subject matter may contain "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995. These statements can be identified by introductory words such as "expects," "plan," "believes," "will," "achieve," "anticipate," "would," "should," "subject to" or words of similar meaning, and by the fact that they do not relate strictly to historical or current facts. Forward-looking statements frequently are used in discussing potential product applications, potential collaborations, product development activities, clinical studies, regulatory submissions and approvals, and similar operating matters. Many factors may cause actual results to differ from forward-looking statements, including inaccurate assumptions and a broad variety of risks and uncertainties, some of which are known and others of which are not. Known risks and uncertainties include those identified from time to time in the reports filed by Generex with the Securities and Exchange Commission, which should be considered together with any forward-looking statement. No forward-looking statement is a guarantee of future results or events, and one should avoid placing undue reliance on such statements. Generex undertakes no obligation to update publicly any forward-looking statements, whether as a result of new information, future events or otherwise. Generex claims the protection of the safe harbor for forward-looking statements that is contained in the Private Securities Litigation Reform Act.

Generex Contact:

Generex Biotechnology Corporation

Joseph Moscato 646-599-6222

Todd Falls 1-800-391-6755 Extension 222 investor@generex.com

The rest is here:
Generex Biotechnology Subsidiary Olaregen Therapeutix Announces Publication on the Use of Excellagen for Vascular Repair - GlobeNewswire

New Jersey, United States,- Verified Market Researchhas recently published an extensive report on the Regenerative Medicine Market to its ever-expanding research database. The report provides an in-depth analysis of the market size, growth, and share of the Regenerative Medicine Market and the leading companies associated with it. The report also discusses technologies, product developments, key trends, market drivers and restraints, challenges, and opportunities. It provides an accurate forecast until 2027. The research report is examined and validated by industry professionals and experts.

The report also explores the impact of the COVID-19 pandemic on the segments of the Regenerative Medicine market and its global scenario. The report analyzes the changing dynamics of the market owing to the pandemic and subsequent regulatory policies and social restrictions. The report also analyses the present and future impact of the pandemic and provides an insight into the post-COVID-19 scenario of the market.

Global Regenerative Medicine Market was valued at USD 24.96 billion in 2019 and is projected to reach USD 121.01 billion by 2027, growing at a CAGR of 23.54% from 2020 to 2027.

The report further studies potential alliances such as mergers, acquisitions, joint ventures, product launches, collaborations, and partnerships of the key players and new entrants. The report also studies any development in products, R&D advancements, manufacturing updates, and product research undertaken by the companies.

Leading Key players of Regenerative Medicine Market are:

Competitive Landscape of the Regenerative Medicine Market:

The market for the Regenerative Medicine industry is extremely competitive, with several major players and small scale industries. Adoption of advanced technology and development in production are expected to play a vital role in the growth of the industry. The report also covers their mergers and acquisitions, collaborations, joint ventures, partnerships, product launches, and agreements undertaken in order to gain a substantial market size and a global position.

Regenerative Medicine Market, By Product:

1.1 Overview1.2 Cell-Based Products1.2.1 Allogeneic Products1.2.2 Autologous Products1.3 Acellular Products

Regenerative Medicine Market, By Therapy:

2.1 Overview2.2 Tissue Engineering2.3 Immunotherapy2.4 Gene Therapy2.5 Cell Therapy2.6 Others

Regenerative Medicine Market, By Application:

3.1 Overview3.2 Central Nervous System Diseases3.3 Oncology3.4 Diabetes3.5 Orthopedic & Musculoskeletal Disorders3.6 Dermatology3.7 Cardiology3.8 Others

Regional Analysis of Regenerative Medicine Market:

A brief overview of the regional landscape:

From a geographical perspective, the Regenerative Medicine Market is partitioned into

North Americao U.S.o Canadao MexicoEuropeo Germanyo UKo Franceo Rest of EuropeAsia Pacifico Chinao Japano Indiao Rest of Asia PacificRest of the World

Key coverage of the report:

Other important inclusions in Regenerative Medicine Market:

About us:

Verified Market Research is a leading Global Research and Consulting firm servicing over 5000+ customers. Verified Market Research provides advanced analytical research solutions while offering information enriched research studies. We offer insight into strategic and growth analyses, Data necessary to achieve corporate goals, and critical revenue decisions.

Our 250 Analysts and SMEs offer a high level of expertise in data collection and governance use industrial techniques to collect and analyze data on more than 15,000 high impact and niche markets. Our analysts are trained to combine modern data collection techniques, superior research methodology, expertise, and years of collective experience to produce informative and accurate research.

Contact us:

Mr. Edwyne Fernandes

US: +1 (650)-781-4080UK: +44 (203)-411-9686APAC: +91 (902)-863-5784US Toll-Free: +1 (800)-7821768

Email: [emailprotected]

Continue reading here:
Regenerative Medicine Market Size by Top Companies, Regions, Types and Application, End Users and Forecast to 2027 - Bulletin Line

HONG KONG Singapore-based Tessa Therapeutics Pte. Ltd. released the results of two investigator-initiated phase I/II trials that found its autologous CD30 CAR T-cell therapy TT-11 showed a high rate of durable complete responses and a favorable safety profile in patients with relapsed/refractory Hodgkin lymphoma.

The studies, funded by Tessa, were led by researchers at the Baylor College of Medicine and the University of North Carolina (UNC) Lineberger Comprehensive Cancer Center.

The trials enrolled 41 adult patients who received CD30 CAR T-cell therapy following lymphodepletion with chemotherapy. The overall response rate in the 32 patients with active disease who received fludarabine-based lymphodepletion was 72%, including 19 patients (59%) with complete responses.

Among those who participated in the studies, 94% were still alive a year after treatment and 61% of those who had a complete response also reported no evidence of recurrence a year later.

None of the patients experienced complications that have been seen with several CD19 CAR T cell trials. The results have been published in the Journal of Clinical Oncology.

These data are significant, as they demonstrate that CAR T-cell therapy may be a safe and effective treatment option for patients with Hodgkin lymphoma and potentially other lymphomas expressing the CD30 antigen, said Natalie Grover, study co-first author, assistant professor in the UNC Department of Medicine and a UNC Lineberger member.

The highest dose treatment led to the complete disappearance of tumors in the majority of patients, and almost all subjects had clinical benefit. As such, we believe further study of this treatment approach is warranted, said Carlos Ramos, study co-first author, professor at the Center for Cell and Gene Therapy at Baylor College of Medicine, Houston Methodist Hospital and Texas Childrens Hospital.

Expanded testing to come

Ivan Horak, Tessas president of R&D, told BioWorld that the company plans to further explore the results in a Tessa-sponsored regulatory phase II trial, which it aims to initiate this year. The TT-11 trial would be conducted out of 22-plus sites in U.S. and Europe, he said.

The companys clinical trial partners include institutions in the U.S. such as MD Anderson, Baylor College of Medicine, Stanford Cancer Institute, City of Hope National Medical Center, UCSF Medical Center and Baylor Scott & White Health, as well as other centers in Massachusetts, Texas and California.

The University of North Carolina has granted Tessa an exclusive license to its patents, data and know-how, while Baylor College of Medicine has granted Tessa the rights to use its data and know-how, for the further development and commercialization of this therapy. Tessa declined to speak on the financial arrangements given confidentiality considerations.

Tessa's pipeline currently has four IND-approved clinical trials, covering the evaluation of TT-11 in Hodgkins lymphoma the companys lead program, which has a regenerative medicine advanced therapy designation and non-Hodgkin lymphomas, as well as trials for TT-11X and TT-16. It also has one preclinical program for a candidate known as TT-20X, which will explore allogeneic dual CAR Epstein-Bar virus-specific T cells in solid tumors. The company also plans to test TT-11 (HL) in pediatric patients, Horak said.

TT-11X, the companys allogeneic candidate, combines the properties of CD30-CAR and virus specific T-cells (VSTs) in an allogeneic setting. VSTs can be used for allogeneic application without T-cell antigen receptor (TCR) deletion or other genetic modifications, with a minimal risk of graft rejection, Horak said. CD30-CAR as a target has shown strong efficacy in Hodgkin lymphoma and further increases the persistence and expansion of VST cells, he said.

TT-16 is in an upcoming investigator-initiated phase I trial in HER2-positive solid tumors. The FDA has approved the trial to commence at Baylor College of Medicine.

Tessa also is building an in-house 90,000-square-foot GMP facility, which will be one of the companys commercial-scale cell therapy manufacturing facilities in Asia.

Read this article:
Tessa enjoys positive results from two phase I/II trials of CD30 CAR T-cell therapy - BioWorld Online

With this research service, our Transformational Health team provides critical insights into the global biologics industry highlighting the growth opportunities, market revenue segmentation, and technology trends influencing its growth.

New York, Aug. 11, 2020 (GLOBE NEWSWIRE) -- Reportlinker.com announces the release of the report "Curative Oncology and Rare Disease Therapies Transforming the Global Biologics Market, 20202024" - https://www.reportlinker.com/p05950884/?utm_source=GNW The global biologics market covered in this study includes 4 major segments antibody therapies, recombinant proteins, vaccines, and regenerative medicine.

The forecast for the global biologics market till 2024 reveals interesting trend and paradigm shifts that are set to take place in the industry. Importantly, the study also identifies actionable growth opportunities for industry participants to profit upon.This research service identifies the largest revenue-generating segments and key therapeutic areas for the global biologics industry. Accelerated regulatory approvals for biologic products and the emergence of next-generation technologies are highlighted, in addition to their influence on market trends during the forecast period. The study highlights the dynamics of the biologics industry and the sub-segments of the biologics market. Growth opportunities in antibody-drug conjugate (ADC), RNA therapy, and gene therapy platforms are also explored. Further, the study discusses the impact (such as the accelerated development of vaccines) of the COVID-19 pandemic on the biologics industry and the market. Current challenges facing the biologics industry such as the sluggish growth rate of vaccines, and recombinant proteins are discussed. Most importantly, this research service discusses possible future market trends such as the accelerated development of mRNA-based vaccines and the increasing importance of specialty bio-CDMOs for the development and commercialization of regenerative medicine. Based on the market trends and revenue forecasts, our group of analysts highlight key growth opportunities in ADC, RNA, and gene therapy platforms through successful drug launches such as Belantamab Malfodotin, Inclisiran, and Zolgensma.Read the full report: https://www.reportlinker.com/p05950884/?utm_source=GNW

About ReportlinkerReportLinker is an award-winning market research solution. Reportlinker finds and organizes the latest industry data so you get all the market research you need - instantly, in one place.

__________________________

Link:
Curative Oncology and Rare Disease Therapies Transforming the Global Biologics Market, 20202024 - Yahoo Finance